CSIMarket
 
Crispr Therapeutics Ag  (CRSP)
Other Ticker:  
 
 
Price: $72.9500 $0.94 1.305%
Day's High: $73.5 Week Perf: -5.04 %
Day's Low: $ 71.40 30 Day Perf: -7.7 %
Volume (M): 1,940 52 Wk High: $ 91.10
Volume (M$): $ 141,530 52 Wk Avg: $57.69
Open: $71.78 52 Wk Low: $37.55



 Market Capitalization (Millions $) 5,793
 Shares Outstanding (Millions) 79
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -354
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 15

Crispr Therapeutics Ag
CRISPR Therapeutics AG is a biotechnology company that focuses on developing novel therapies using CRISPR gene-editing technology. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows precise modifications of genetic material.

The company aims to develop transformative gene-based medicines for serious diseases by utilizing the power of CRISPR. It has a diversified pipeline of potential gene therapies that target a range of genetic disorders, including blood disorders, oncology, regenerative medicine, and rare diseases.

CRISPR Therapeutics AG collaborates with leading academic institutions and pharmaceutical companies to advance its research and development efforts. The company has also established strategic partnerships to support the commercialization and global distribution of its potential therapies.

The company's scientific expertise and cutting-edge technology have garnered significant attention in the biotechnology industry and have the potential to revolutionize the treatment of genetic diseases. As a pioneer in the field of CRISPR gene editing, CRISPR Therapeutics AG continues to push the boundaries of modern medicine and holds great promise for improving patient outcomes.


   Company Address: Baarerstrasse 14 Zug 6300
   Company Phone Number: 561 32 77   Stock Exchange / Ticker: NASDAQ CRSP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Strategic Investment by EcoR1 Capital and SR One Propels Crispr Therapeutics Ag to New Heights

Published Tue, Feb 13 2024 1:30 PM UTC


In a game-changing move for Crispr Therapeutics Ag, new investor EcoR1 Capital and SR One have led a significant round of funding with participation from existing and new investors. This strategic investment is set to have a profound impact on shareholders, as well as the future growth and success of the company.
With 79.414098 million shares outstanding and a curre...

Clinical Study

A New Era in Genetic Medicine: European Commission Approves Groundbreaking CRISPR/Cas9 Therapy for Sickle Cell Disease and Beta Thalassemia, as CRISPR Therapeutics Ventures into Immuno-Oncology and Autoimmune Disease

Published Tue, Feb 13 2024 7:30 AM UTC

For the first time, a revolutionary gene-editing therapy called CASGEVY (exagamglogene autotemcel) has been authorized by the European Commission for the treatment of both Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT). This landmark decision offers hope to over 8,000 patients aged 12 years and older suffering from severe forms of these debilitati...

Product Service News

Transforming Beta Thalassemia Treatment: FDA Approval of CASGEVY, a One-time CRISPR Therapeutics Solution Transforms Patient Prospects

Published Tue, Jan 16 2024 9:01 PM UTC

The field of gene editing and therapeutic techniques has recently witnessed a monumental stride as the FDA (U.S. Food and Drug Administration) sanctions a pioneer gene-editing treatment for Transfusion-Dependent Beta Thalassemia (TDT). The approach, CASGEVY (exagamglogene autotemcel), manufactured by CRISPR Therapeutics, manifests an innovative potential for gene-editing tec...

Clinical Study

CRISPR Therapeutics Harnesses the Power of Gene Editing: Revolutionizing Immuno-Oncology and Autoimmune Disease Treatment

Published Mon, Dec 4 2023 9:15 PM UTC

CRISPR Therapeutics: Pioneering the Future of Immuno-Oncology and Autoimmune Disease Treatment

In a groundbreaking announcement, CRISPR Therapeutics, a leading gene-editing company, unveiled updates to their immuno-oncology pipeline along with a bold expansion into autoimmune disease therapeutics. The preliminary data from ongoing clinical trials presented immense p...

Crispr Therapeutics Ag

Crispr Therapeutics Ag's Revenue Plunges, Raising Concerns for the Biotech & Pharma Industry



In the dynamic world of finance, it is often fascinating to witness the rise and fall of companies and gauge their performance based on financial results. Crispr Therapeutics Ag, a cutting-edge biotech company at the forefront of gene editing technology, has recently unveiled its latest financial results. These figures offer us a glimpse into the company's progress and shed light on its potential for future growth.
Improving Financials:
Crispr Therapeutics Ag's recently released financials demonstrate an encouraging trend of financial improvements. Over the most recent fiscal period, the company showcased a reduced loss per share, reporting losses of $-1.41 per share compared to $-2.24 per share the previous year. Furthermore, it managed to decrease the shortfall from $-0.98 per share during the prior financial reporting period.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com